Executive Leadership Change at Mirador Therapeutics
In an important development for Mirador Therapeutics, a leader in precision medicine, the company has announced that Gregg Gilbert will take on the role of chief financial officer. With over 25 years of experience in biopharma equity research and investment banking, Gilbert is set to be a key player in advancing the company’s mission.
Leadership Insights
The news has sparked excitement from Mirador’s Chairman and CEO, Mark C. McKenna, who is thrilled about the timing of Gilbert's appointment. “Since launching earlier this year with more than $400 million in capital, the Mirador team is determined to quickly grow our portfolio,” McKenna remarked, emphasizing how Gilbert’s expertise is crucial at this significant juncture.
Strategic Timing for Expansion
McKenna also pointed out that Gilbert’s vast experience on Wall Street, alongside his unique understanding as both a corporate leader and an investor, will prove essential for Mirador. His insights are expected to steer the company into its next chapter, focusing on innovative therapies for immunology and inflammation (I&I).
Gilbert's Notable Experience
Prior to his role at Mirador, Gilbert was a managing director at Bank of America Securities, where he specialized in healthcare investment banking. His work involved advising life sciences companies at various stages, particularly in capital raising, mergers, and acquisitions. Additionally, Gilbert earned recognition as a leading equity research analyst during his lengthy tenure at Bank of America Merrill Lynch, where he was included in Institutional Investor’s All-America Research Team over ten times.
Expanding His Leadership Scope
Gilbert's impressive career also features significant positions at Deutsche Bank and Truist Securities, and he began his professional journey as an analyst at Goldman Sachs. His diverse experiences in investment and analysis will allow him to offer strategic insights that align with Mirador’s goals.
Dedication to Stakeholders
Gilbert is excited about his new position, stating, “Mirador is on a remarkable path to delivering value for shareholders and ultimately helping millions with immune-mediated and inflammatory diseases.” His commitment to making a positive difference through teamwork reflects his alignment with the company's core values and aspirations.
About Mirador Therapeutics
Mirador Therapeutics leads the way in precision medicine by developing innovative therapeutics focused on immunology and inflammation. The company aims to redefine how precision medicine is understood and used, utilizing its proprietary Mirador360 development engine. This advanced platform emphasizes innovative biology, multi-modal data, and analytics, all aimed at rapidly advancing new treatments for individuals suffering from chronic immune-mediated inflammatory and fibrotic conditions.
Launched in 2024, Mirador has successfully raised an impressive $400 million from esteemed life sciences investors. With a strong foundation in San Diego, CA, Mirador is committed to pushing the limits of medicine to tackle significant health issues. For more information, interested individuals can visit www.miradortx.com and follow the company on LinkedIn.
Frequently Asked Questions
Who is the new CFO of Mirador Therapeutics?
The new CFO is Gregg Gilbert, who brings over 25 years of experience in the biopharma industry.
What previous roles has Gregg Gilbert held?
Before joining Mirador, Gilbert was a managing director at Bank of America Securities, focusing on healthcare investment banking.
What does Mirador Therapeutics specialize in?
Mirador is dedicated to developing first-in-class or best-in-class therapies targeting immunology and inflammation.
How much funding has Mirador managed to raise?
Mirador has successfully raised over $400 million from leading investors in life sciences.
What is Mirador Therapeutics' location?
The company is headquartered in San Diego, California.
